Solara Active Pharma Sciences has informed that the Meeting of the Rights Issue Committee of the Board of Directors of the Company held today, Tuesday, March 24, 2026 has considered and approved the making of Second & Final call of ? 112.50/- per equity shares (? 3.00/- towards face value and ? 109.50/- towards securities premium) per Rights Share in respect of partly-paid Rights Shares, on Rights basis, pursuant to the Letter of Offer dated May 09, 2024. Rights Issue Committee has fixed Thursday, April 02, 2026, as the Record date for the purpose of determining the holders of partly paid-up Equity Shares to whom the call notice will be dispatched for payment of the call. Details under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 has been enclosed as Annexure I. The Rights Issue Committee Meeting commenced at 9.30 am and concluded at 9.55 am.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1696.65 |
| Dr. Reddys Lab | 1218.30 |
| Cipla | 1226.65 |
| Zydus Lifesciences | 936.00 |
| Lupin | 2339.20 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: